Anti-Vascular Endothelial Growth Factor Therapy for Complications of Diabetic Retinopathy-From Treatment to Prevention?

Tien-En Tan^{1

2}, Sobha Sivaprasad³, Tien Yin Wong^{1

2

4}

Affiliations

¹ Singapore Eye Research Institute, Singapore, Singapore National Eye Centre, Singapore.
² Duke-National University of Singapore Medical School, Singapore.
³ National Institute of Health and Care Research, UCL and Moorfields Eye Hospital, London, United Kingdom.
⁴ Tsinghua Medicine, Tsinghua University, Beijing, China.

Editorial

Tien-En Tan et al. JAMA Ophthalmol. 2023.

. 2023 Mar 1;141(3):223-225.

doi: 10.1001/jamaophthalmol.2023.0496.

Tien-En Tan^{1

2}, Sobha Sivaprasad³, Tien Yin Wong^{1

2

4}

¹ Singapore Eye Research Institute, Singapore, Singapore National Eye Centre, Singapore.
² Duke-National University of Singapore Medical School, Singapore.
³ National Institute of Health and Care Research, UCL and Moorfields Eye Hospital, London, United Kingdom.
⁴ Tsinghua Medicine, Tsinghua University, Beijing, China.

No abstract available

Comment on

Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
Maturi RK, Glassman AR, Josic K, Baker CW, Gerstenblith AT, Jampol LM, Meleth A, Martin DF, Melia M, Punjabi OS, Rofagha S, Salehi-Had H, Stockdale CR, Sun JK; DRCR Retina Network. Maturi RK, et al. JAMA. 2023 Feb 7;329(5):376-385. doi: 10.1001/jama.2022.25029. JAMA. 2023. PMID: 36749332 Free PMC article.